Pharmaceutical Maker Petitions Supreme Court to Restore Abortion Pill Access by Mail
Danco Laboratories filed an emergency request after a federal appeals court reinstated requirements that patients obtain mifepristone in person.
Primary source: BBC World News. Full source links and update notes are below.
Fast summary
Start here
- Danco Laboratories is seeking an emergency pause on a Fifth Circuit ruling that curbs mail-order access to mifepristone.
- The Fifth Circuit's decision reinstated a requirement that abortion pills be obtained in person, affecting telemedicine services.
- The legal battle stems from a lawsuit led by Louisiana challenging the FDA's 2023 decision to allow mail-order dispensing.
What happened
Danco Laboratories, the manufacturer of the abortion pill mifepristone, has filed an emergency appeal with the US Supreme Court. The company is asking the court to block a ruling from the Fifth Circuit Court of Appeals that restricted how the drug can be distributed, effectively halting the ability for providers to send the medication via mail.
What's new in this update
On Saturday, Danco's lawyers argued that the Fifth Circuit's decision to reinstate in-person dispensing requirements would cause "irreparable harm" and "chaos" for patients and providers. This appeal follows a Friday order from the appeals court that temporarily reinstated restrictions which had been lifted by the FDA in 2023.
Key details
The Fifth Circuit's order overrides a previous lower court ruling that had paused the case during a Trump administration review of FDA regulations. In its ruling, the appeals court cited Louisiana’s interests, stating that mail-order access undermines state policies regarding fetal personhood. Conversely, New York Attorney General Letitia James clarified that abortion access will remain protected within her state regardless of the federal appellate ruling.
Background and context
In 2023, the FDA permanently removed the requirement for in-person visits to obtain mifepristone, allowing the drug to be prescribed via telemedicine and delivered by mail. While the Supreme Court rejected a separate effort to restrict the drug in 2024 based on legal standing, that decision left the door open for subsequent challenges like the current lawsuit brought by the state of Louisiana.
What to watch next
The US Supreme Court must now decide whether to grant Danco's request for an emergency stay. If the court does not intervene, the in-person requirement will remain in effect while the broader legal challenge proceeds, significantly limiting access in states where abortion is banned or restricted.
Why it matters
Medication abortion is the most common method of terminating pregnancies in the US, and mail access is a primary tool for patients in restrictive states.
Read next
Follow this story through the topic hub, more world coverage, and the latest updates.
Weekly briefing
Get the week's key developments in one concise email.
Get a fast catch-up on the biggest stories, the context behind them, and the links worth your time.
Cadence
Weekly, for a quick catch-up
Coverage
AI, business, world, security, sports
Format
Clear takeaways and useful context
Request the briefing
Leave your email to open a prepared request and get on the list for the weekly briefing.
Author
See who assembled this story and follow more of their work.
Sources and methodology